# US 2010/0303866 A1 · Immunogenic peptides and their use in immune disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303866 A1
- Document ID: US20100303866A1
- Status: Published application
- Kind: A1
- Application number: 12/377,048
- Filed: 2007-08-13
- Published: 2010-12-02
- Earliest claimed: 2006-08-11
- Assignees: Desire Collen Research Foundation vzw
- Inventors: Jean-Marie Saint-Remy
- Web page: https://patentgrep.com/patent/US20100303866A1

## CPC

- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/35: Allergens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/40: characterised by antigens that are targeted or presented by cells of the immune system
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/48: Allergens
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/415: from plants
- C07K 14/43531: {from mites}
- C07K 14/47: from mammals
- C07K 14/4717: {Plasma globulins, lactoglobulin}
- C07K 14/62: Insulins
- C12N 9/0065: {acting on hydrogen peroxide as acceptor (1.11)}
- C12N 9/88: Lyases (4.)
- A61K 2039/572: {cytotoxic response}
- C07K 2319/00: Fusion polypeptide
- C12Y 111/01008: Iodide peroxidase (1.11.1.8)
- C12Y 401/01015: Glutamate decarboxylase (4.1.1.15)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

An isolated immunogenic peptide derived from an antigenic protein comprising an artificial sequence comprising:
a T cell epitope of said antigenic protein; and
motif C—X(2)-[CST] or [CST]-X(2)-C, said motif being either adjacent to said epitope, or separated from said epitope by a linker of at most 7 amino acids,

### Claim 38 (depends on 37)

The isolated immunogenic peptide according to claim 37 wherein said motif does not naturally occur within a region of 11 amino acids N-terminally or C-terminally of the T-cell epitope in said protein.

### Claim 39 (depends on 37)

The isolated immunogenic peptide according to claim 37 wherein the motif is C—X(2)-C, said motif being either adjacent to said epitope, or separated from said epitope, by a linker of at most 7 amino acids.

### Claim 40 (depends on 37)

The isolated immunogenic peptide according to claim 37 wherein the motif is C—X(2)-[ST] or [ST]-X(2)-C, said motif being either adjacent to said epitope, or separated from said epitope, by a linker of at most 7 amino acids, wherein, if said motif is C—X(2)-S or S—X(2)-C, said T cell epitope does not comprise the sequence EPCIIHRGKP (SEQ ID. NO: 1) of the p21-35 peptide of Der p 2.

### Claim 41 (depends on 40)

The isolated immunogenic peptide according to claim 40, wherein, if said motif is C—X(2)-S or S—X(2)-C, said antigenic protein is not Der p 2.

### Claim 42 (depends on 37)

The isolated immunogenic peptide according to claim 37, wherein said artificial sequence has a length of between 12 and 19 amino acids.

### Claim 43 (depends on 37)

The isolated immunogenic peptide according to claim 37, wherein the antigenic protein is an auto-antigen or an allergen.

### Claim 44 (depends on 37)

A method of treating or preventing an auto-immune disorder in an individual, comprising the steps of administering an isolated immunogenic peptide according to claim 37 to said individual, wherein the immunogenic peptide is derived from an auto-antigenic protein.

### Claim 45 (depends on 37)

A method of treating or reducing the symptoms of an allergic condition in an individual, comprising the steps of administering an isolated immunogenic peptide according to claim 37 to said individual, wherein the immunogenic peptide is derived from an allergen.

### Claim 46 (depends on 37)

A method of treating or preventing an allergic condition or an auto-immune disorder in an individual, comprising the steps of:
providing peripheral blood cells of said individual,
contacting said cells with an antigenic peptide according to claim 37,
expanding said cells, and
administering said expanded cells to said individual.

### Claim 47

A method for preparing a peptide of an antigenic protein capable of eliciting cytolytic CD4+ T cell activity said method comprising the steps of:
providing a peptide sequence consisting of a T-cell epitope of said antigenic protein, and linking to said peptide sequence a sequence comprising motif C—X(2)-C, such that said motif and said epitope are either adjacent to each other or separated by a linker of at most 7 amino acids.

### Claim 48

A method for preparing a peptide of an antigenic protein capable of eliciting cytolytic CD4+ T cell activity said method comprising the steps of:
providing a peptide sequence consisting of a T-cell epitope of said antigenic protein, wherein the motif C—X(2)-[CST] or [CST]-X(2)-C does not naturally occur within a region of 11 amino acids N-terminally or C-terminally of the T-cell epitope in said protein, and
linking to said peptide sequence a sequence comprising motif C—X(2)-[CST] or [CST]-X(2)-C, such that said motif and said epitope are either adjacent to each other or separated by a linker of at most 7 amino acids.

### Claim 49

A method for preparing a peptide of an antigenic protein capable of eliciting cytolytic CD4+ T cell activity said method comprising the steps of:
providing a peptide sequence consisting of a T-cell epitope of said antigenic protein, and linking to said peptide sequence a sequence comprising motif C—X(2)-[CST] or [CST]-X(2)-C, such that said motif and said epitope are either adjacent to each other or separated by a linker of at most 7 amino acids,
wherein, where said motif is C—X(2)-S or S—X(2)-C said T-cell epitope does not comprise the sequence EPCIIHRGKP (SEQ ID. NO: 1) of the p21-35 peptide of Der p 2.

### Claim 50 (depends on 49)

The method of claim 49, wherein said antigenic protein is not Der p 2.

### Claim 51 (depends on 49)

The method of claim 49, which further comprises modifying the sequence of said peptide by modifying the amino acids in the epitope, thereby ensuring that in said modified peptide the sequence of the epitope is modified such that ability to fit into the MHCII cleft is maintained.

### Claim 52

A method for preparing an isolated immunogenic peptide of an antigenic protein capable of eliciting cytolytic CD4+ T cell activity said method comprising the steps of:
(a) identifying within said antigenic protein a sequence comprising a T cell epitope flanked, in said antigenic protein by motif C—X(2)-[CST] or [CST]-X(2)-C within a region of 11 amino acids N-terminally or C-terminally of said T-cell epitope; and
(b) generating a peptide comprising said sequence as an isolated peptide of between 12 and 19 amino acids,
wherein said antigenic protein is not Der p 2.

### Claim 53 (depends on 52)

The method of claim 52, which further comprises modifying the sequence of said peptide by modifying the amino acids in the motif and/or by modifying the number of amino acids between the motif and the epitope and/or by modifying the epitope sequence, thereby ensuring that in said modified peptide:
the ability of the T cell epitope to fit into the MHCII cleft is maintained,
the motif is conserved, and
said motif and said epitope remain adjacent to each other or separated by a linker of at most 7 amino acids.

### Claim 54 (depends on 52)

The method according to claim 52, which further comprises the step of attaching a late endosomal targeting sequence to the peptide obtained in step (b).

### Claim 55

A method of identifying a population of cytotoxic Tregs which comprises determining that, the cells have the following characteristics:
the cells express CD4,
the cells do not express IL-10 or TGF-beta, and
the cells express Krox-20 and produce granzymes and Fas ligand.

### Claim 56

A method of identifying a population of cytotoxic Tregs which comprises determining one or more of the following characteristics, when compared to non-cytotoxic Tregs:
an increased expression of surface markers including CD103, CTLA-4, FasL, and ICOS upon activation,
a high expression of CD25, expression of CD4, ICOS, CTLA-4, GITR and low or no expression of CD127 (IL7-R),
the expression of transcription factor T-bet and/or egr-2 (Krox-20) but not of the transcription repressor Foxp3,
a high production of IFN-gamma and no or only trace amounts of IL-10, IL-4, IL-5, IL-13 or TGF-beta, and
an increased expression of markers including FasL and granzymes B and C upon activation.

### Claim 57 (depends on 56)

The method according to claim 56, which further comprises determining that these cells do not respond to the activation by TCR recognition.

### Claim 58 (depends on 37)

A method for obtaining a population of antigen-specific regulatory T cells with cytotoxic properties, the method comprising the steps of:
providing peripheral blood cells,
contacting said cells with an immunogenic peptide according to claim 37, and
expanding said cells in the presence of IL-2.

### Claim 59 (depends on 37)

A method for obtaining a population of antigen-specific regulatory T cells with cytotoxic properties, the method comprising the steps of:
providing an immunogenic peptide according to claim 37, administering said peptide to a subject, and
obtaining said population of antigen-specific regulatory T cells from said subject.

### Claim 60 (depends on 58)

The population of T regulatory cells obtainable by the method of claim 58 for use in the treatment and prevention of an allergic condition or an auto-immune disorder.

### Claim 61 (depends on 59)

The population of T regulatory cells obtainable by the method of claim 59 for use in the treatment and prevention of an allergic condition or an auto-immune disorder.
